Dizlin – Dizlin Pharmaceuticals AB

Parkinson’s Disease

Parkinson´s disease is a progressive neurodegenerative disorder.

The unique features of Infudopa™

Our products in development

“I have an ethical responsibility to contribute to Infudopa^™ becoming available to patients suffering from Parkinson’s disease”

– Arvid Carlsson (1923-2018) who received the Nobel prize in 2000 for the discoveries that paved the way for the introduction of levodopa as treatment for Parkinson´s disease.

New report suggests that Dizlin´s product aimed for subcutaneous administration, Infudopa SubC, will prove to be as effective as Duodopa for the treatment of Parkinson´s disease

Dizlin Pharmaceuticals AB, a research-based pharmaceutical development company with focus on diseases of the central nervous system, today announces that the paper “Motor Efficacy of Subcutaneous DIZ102, Intravenous DIZ101 or Intestinal Levodopa/Carbidopa Infusion” was published [...]

CEO Letter, Year End 2023

With the capital we raised in September/October, we have been able to complete both the user study for the pump and the preclinical program. We know that both projects have gone well, although we have [...]

Dizlin Pharmaceuticals presented efficacy data from the IPO-001 pharmacokinetic cross-over study comparing Infudopa SubC (DIZ102), Infudopa IntraV (DIZ101), and LCIG (Duodopa) at the International Congress of Parkinson´s Disease and Movement Disorders in Copenhagen

Gothenburg, Sweden, September 13, 2023 – Dizlin Pharmaceuticals AB, a research-based pharmaceutical development company with focus on diseases of the central nervous system, has presented efficacy data from the IPO-001 pharmacokinetic cross-over study comparing Infudopa [...]

Read all news

Dizlin Pharmaceuticals is a pharmaceutical research company developing new innovative treatments for late stages of Parkinson´s disease.

We have developed two products, containing levodopa-carbidopa solutions, for the treatment of advanced Parkinson´s disease.

Parkinson’s Disease

The unique features of Infudopa™

Our products in development

“I have an ethical responsibility to contribute to Infudopa^™ becoming available to patients suffering from Parkinson’s disease”

New report suggests that Dizlin´s product aimed for subcutaneous administration, Infudopa SubC, will prove to be as effective as Duodopa for the treatment of Parkinson´s disease

CEO Letter, Year End 2023

Dizlin Pharmaceuticals presented efficacy data from the IPO-001 pharmacokinetic cross-over study comparing Infudopa SubC (DIZ102), Infudopa IntraV (DIZ101), and LCIG (Duodopa) at the International Congress of Parkinson´s Disease and Movement Disorders in Copenhagen

Tracking Cookies

Third Party Embeds

Dizlin Pharmaceuticals is a pharmaceutical research company developing new innovative treatments for late stages of Parkinson´s disease.

We have developed two products, containing levodopa-carbidopa solutions, for the treatment of advanced Parkinson´s disease.

Parkinson’s Disease

The unique features of Infudopa™

Our products in development

“I have an ethical responsibility to contribute to Infudopa™ becoming available to patients suffering from Parkinson’s disease”

New report suggests that Dizlin´s product aimed for subcutaneous administration, Infudopa SubC, will prove to be as effective as Duodopa for the treatment of Parkinson´s disease

CEO Letter, Year End 2023

Dizlin Pharmaceuticals presented efficacy data from the IPO-001 pharmacokinetic cross-over study comparing Infudopa SubC (DIZ102), Infudopa IntraV (DIZ101), and LCIG (Duodopa) at the International Congress of Parkinson´s Disease and Movement Disorders in Copenhagen

Tracking Cookies

Third Party Embeds

“I have an ethical responsibility to contribute to Infudopa^™ becoming available to patients suffering from Parkinson’s disease”